cc-1088
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 1999 (NCT00006097)
Timeline
Indications
Mechanism of action
- Phosphodiesterase 4AINHIBITOR
PDE4A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cc-1088
- cc-1088
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00045786 | Phase 2 | Oct 1, 2001 | Celgene |
| NCT00006097 | Phase 1/Phase 2 (Phase 2) | Aug 1, 1999 | Boston University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boston University | Academic/Hospital | 1 | 1 | 1 | 1999 |
| Celgene | For profit | 1 | 1 | 1 | 2001 |
2 organizations
Page 1 / 1